S42 - Update in Muscular Dystrophy

Event Time: Thursday April 27, 2017 1:00 pm to 3:00 pm
Topic(s): Neuromuscular and Clinical Neurophysiology (EMG)
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Eteplirsen for the Treatment of Duchenne Muscular Dystrophy (DMD) JS Charleston
Disclosure:
Dr. Charleston has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics.

1:12 PM 002 Genetic landscape of Limb-Girdle Muscular Dystrophies from a Large Cohort of Neuromuscular Disease Patients Samya Chakravorty
Disclosure:
Dr. Chakravorty has nothing to disclose.

1:24 PM 003 Therapeutic Effect of KPT-350 in a Preclinical Model of Duchenne Muscular Dystrophy Devin Gibbs
Disclosure:
Dr. Alexander has nothing to disclose.

1:36 PM 004 Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) and Loss of Ambulation (LOA) JR Mendell
Disclosure:
Investigator for Sarepta Therapeutics, Inc. clinical trial(s) Attended global advisory board for Sarepta Therapeutics, Inc..

1:48 PM 005 Genetic markers of myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) in human urine Layal Antoury
Disclosure:
Dr. Antoury has nothing to disclose.

2:00 PM 006 Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 distal and proximal muscles Giovanni Meola, MD, FAAN
Disclosure:
Dr. Meola has nothing to disclose.

2:12 PM 007 Cardiac function in the dystroglycanopathies Julia Collison
Disclosure:
Dr. Collison has nothing to disclose.

2:24 PM 008 Development of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Treatment of Duchenne Muscular Dystrophy (DMD) P Duda
Disclosure:
Dr. Frank has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics.

Register Now

Related Courses